再鼎医药（09688.HK）今日盘中大跌10.01%，引起市场广泛关注。这一显著跌幅或与公司近期发布的2025年上半年业绩报告有关。
根据再鼎医药公布的中期业绩，公司截至2025年6月30日的六个月内，总收入为2.17亿美元，同比下降15.4%。尽管亏损净额从去年同期的1.34亿美元收窄至8,917万美元，但公司仍未能实现盈利。每股亏损为8美分。
值得注意的是，再鼎医药第二季度的表现有所改善。单季度总收入达1.1亿美元，环比增长9%。同时，调整后经营亏损收窄37%至3,420万美元。公司表示，正稳步迈向2025年第四季度实现盈利的目标。然而，投资者似乎对公司当前的财务状况和短期内持续亏损的前景表示担忧，导致股价出现大幅下跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.